Skip navigation

Dr David Tetard

Senior Lecturer

Department: Applied Sciences

I am an organic chemist who is designing novel powerful metal chelators, with a focus on Fe(III) that can have therapeutic applications, in particular against cancer, neurodegenerative diseases (Parkinson's Disease, Alzheimer's Disease) and as biostatic agents against micro-organisms. My molecules are based on rationale design, trying to optimise metal chelator and other functions such as cell penetration, multiple mode of action, targeting.

David Tetard

Research Themes and Scholarly Interests

Metal chelators as therapeutic compounds, in particular in cancer, neurodegenerative diseases and as biostatic agents against microorganisms.

We focus on the design of powerful Fe(III) chelators of the hydroxypyridinone family that have been demonstrated by us and others to have activity as:

anticancer drugs, interfering with the biochemical processes involving metals (metalloenzymes, oxidative stress)

drugs against neurodegenerative diseases, preventing oxidative damage to neurons

biostatic agents, reducing the rate of growth of microorganisms.

Key Publications

  • Please visit the Pure Research Information Portal for further information
  • A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma, Kyriakou, S., Cheung, W., Mantso, T., Mitsiogianni, M., Anestopoulos, I., Veuger, S., Trafalis, D., Franco, R., Pappa, A., Tetard, D., Panayiotidis, M. 1 Aug 2021, In: Investigational New Drugs
  • Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma, Kyriakou, S., Mitsiogianni, M., Mantso, T., Cheung, W., Todryk, S., Veuger, S., Pappa, A., Tetard, D., Panagiotidis, M. 1 Jun 2020, In: Investigational New Drugs
  • Design and evaluation of bi-functional iron chelators for protection of dopaminergic neurons from toxicants, Gutbier, S., Kyriakou, S., Schildknecht, S., Ückert, A., Brüll, M., Lewis, F., Dickens, D., Pearson, L., Elson, J., Michel, S., Hubscher-Bruder, V., Brandel, J., Tetard, D., Leist, M., Pienaar, I. 1 Sep 2020, In: Archives of Toxicology
  • Novel 1‑hydroxypyridin‑2‑one metal chelators prevent and rescue ubiquitin proteasomal‑related neuronal injury in an in vitro model of Parkinson’s disease, Lewis, F., Farooz, S., Elson, J., Hubscher-Bruder, V., Brandel, J., Soundararajan, M., Smith, D., Dexter, D., Tetard, D., Pienaar, I. Mar 2020, In: Archives of Toxicology
  • The influence of linkages between 1-Hydroxy-2(1H)-pyridinone Coordinating Groups and a Tris(2-aminoethyl)amine core in a novel series of synthetic Hexadentate Iron(III) Chelators on antimicrobial activity, Workman, D., Hunter, M., Wang, S., Brandel, J., Hubscher, V., Dover, L., Tetard, D. 1 Jan 2020, In: Bioorganic Chemistry
  • An Overview of Multifunctional Metal Chelators as Potential Treatments for Neurodegenerative Diseases, Lewis, F., Tetard, D. May 2017, Biometals in Neurodegenerative Diseases: Mechanisms and Therapeutics, San Diego, Elsevier
  • Metal chelating compounds for use in treating diseases, Tetard, D., Lewis, F. 26 May 2016
  • Synthesis of novel Iron(III) chelators based on triaza macrocycle backbone and 1-hydroxy-2(H)-pyridin-2-one coordinating groups and their evaluation as antimicrobial agents, Workman, D., Hunter, M., Dover, L., Tetard, D. Jul 2016, In: Journal of Inorganic Biochemistry
  • Epoxidation of Strained Alkenes Catalysed by (1,2-dimethyl-4(1H)pyridinone-3-olate)2MnIIICl, Robinson-Miller, A., Wyatt, M., Tetard, D. Mar 2015, In: Journal of Molecular Catalysis A: Chemical
  • Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators, Workman, D., Tsatsanis, A., Lewis, F., Boyle, J., Mousadoust, M., Hettiarachchi, N., Hunter, M., Peers, C., Tetard, D., Duce, J. 13 May 2015, In: Metallomics : Integrated Biometal Science

PGR Supervision

  • Sotiris Kyriakou Synthesis and Biological Evaluation of Metal Chelators of the Hydroxypyridinone Family as Potential Treatment of Parkinson’s Disease and Cancer Start Date: 01/10/2016 End Date: 04/03/2020
  • Maryam Mousadoust Synthesis of Novel Ligands Based on Hydroxypyridinones and Hydroxypyranones and their Corresponding Iron (II) / Iron (III) Complexes Start Date: 15/12/2009 End Date: 12/06/2014
  • David Workman Synthesis of High Affinity Iron(III) Chelators for Use as Biostatic Agents Start Date: 01/09/2010 End Date: 27/03/2014
  • Adam Robinson-Miller Study of Mn(II)/Mn(III) Oxidation Catalysts in Alkene Epoxidation and Chromophore Bleaching Start Date: 01/09/2010 End Date: 20/02/2014

Qualifications

  • Teaching & Learning PCAPL October 10 2008
  • Chemistry PhD October 30 1996
  • Fellow (FHEA) Higher Education Academy (HEA) 2013
  • Member (MRSC) Royal Society of Chemistry (RSC) 1998


a sign in front of a crowd
+

Northumbria Open Days

Open Days are a great way for you to get a feel of the University, the city of Newcastle upon Tyne and the course(s) you are interested in.

Research at Northumbria
+

Research at Northumbria

Research is the life blood of a University and at Northumbria University we pride ourselves on research that makes a difference; research that has application and affects people's lives.

a person sitting at a table
+

Order your prospectus

If you would like to know more about our courses, or life in general as a student at Northumbria, then we can help you.

Latest News and Features

More news

Back to top